Significant Setbacks: Why Celgene’s No Longer the Biotech Outperformer It Once Was By: Stocks to Watch December 27, 2017 at 12:01 PM EST A downgrade based on Celgene's drug setbacks is weighing on the biotech's stock today. Read More >>